Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its ...

Dec 31 (Reuters) - UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's (MRK.N), opens new tab therapy to treat a rare lung condition, marking another ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The Merck Future Insight prize was established on the occasion of Merck’s 350th anniversary in 2018 to honour and enable pioneering scientists who are striving to solve some of the biggest ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and ...

(Reuters) -UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's therapy to treat a rare lung condition, marking another win for the drugmaker's potential ...